Nigel Priestley

Dr. Nigel Priestley

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BKBrian R. Kusche
Brian R. Kusche
ASAdrienne E. Smith
Adrienne E. Smith
MMMichele A. McGuirl
Michele A. McGuirl
NPNigel Priestley
Nigel Priestley

6 November 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MEMargaret M. Elmer-Dixon
Margaret M. Elmer-Dixon
ZXZiqing Xie
Ziqing Xie
JAJeremy B. Alverson
Jeremy B. Alverson
NPNigel Priestley
Nigel Priestley
BBBruce E. Bowler
Bruce E. Bowler

1 January 2006 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
JDJennifer M. Dinges
Jennifer M. Dinges
BBBradley A. Bessette
Bradley A. Bessette
JCJames E. Cox
James E. Cox
CRCasey R. Redder
Casey R. Redder
NPNigel Priestley
Nigel Priestley
Methyl nonactate is a valuable starting material for the production of natural product‐like combinatorial libraries and ketide amino acids, a series of novel conformationally constrained amino acid analogues. Fermentation of Streptomyces griseus generates high titers of macrotetrolide antibiotics from which methyl nonactate can be generated by methanolysis. Unfortunately, this approach generates mixtures of homologues that are not economically separable. We report a specific lipase‐mediated hydrolysis of nonactate derivatives that discriminates between homologues and is the foundation of an economically tractable preparation of methyl nonactate in scale.

1 October 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JPJoshua B. Phillips
Joshua B. Phillips
ASAdrienne E. Smith
Adrienne E. Smith
BKBrian R. Kusche
Brian R. Kusche
BBBradley A. Bessette
Bradley A. Bessette
PSP. Whitney Swain
P. Whitney Swain
NPNigel Priestley
Nigel Priestley

23 November 2021 in Journal of Natural Products
Verified
Journal Article
Open access
ASAndrea and Donald Stierle
Andrea and Donald Stierle
DSDonald B. Stierle
Donald B. Stierle
DDDaniel Decato
Daniel Decato
NPNigel Priestley
Nigel Priestley
JAJeremy B. Alverson
Jeremy B. Alverson
DKDorota Klepacki
Dorota Klepacki

1 April 2017 in Journal of Chromatography B
Verified
Journal Article
Open access
JHJohn Hoody
John Hoody
JAJeremy B. Alverson
Jeremy B. Alverson
SKSantosh Keshipeddy
Santosh Keshipeddy
PBPatrick A. Barney
Patrick A. Barney
LWLarissa Walker
Larissa Walker
NPNigel Priestley
Nigel Priestley
Antimicrobial resistance to current antibiotics is a significant public health problem and the need for new antibiotics is a compelling one. We have been developing a new series of antibiotics, propargyl-linked diaminopyrimidines, based on the structure of trimethoprim. To date we have discovered compounds that are effective inhibitors of dihydrofolate reductase (the target of trimethoprim), that are potent antibiotics in vitro against a range of Gram-positive pathogens including methicillin-resistant S. aureus, and that are non-toxic in mammalian cell culture. In this study we report the development of an LC-MS-based protocol for the quantification of our lead antibiotic 37D1-UCP1099 and the application of this assay to follow the concentration of the compound in mouse plasma after intraperitoneal administration. Extraction of 37D1-UCP1099 from mouse plasma was achieved through a liquid-liquid extraction with ethyl acetate. Separation was performed utilizing a reverse-phase C18 column with a ten minute isocratic elution using 47:53 (v/v) 10mM NH4HCO3:acetonitrile. The lower limit of quantitation for 37D1-UCP1099 was 50ngmL-1 and the assay showed a dynamic range of 50-4000ngmL-1 with good linearity (r2≥0.996 for all fits). Intra-day and inter-day precision and accuracy were within 11.3% (%RSD) and 6.6% (%RE) respectably. We have demonstrated that the compound is stable under the assay procedures. The compound was shown to have a mean residence time of 26.2±1.0min and a half-life of 18.2±0.7min after intraperitoneal delivery at 5mgkg-1. These studies now form the foundation of our work to develop additional analogs of 37D1-UCP1099 with improved pharmacokinetic properties.